Vidyya Medical News Service
*
Volume 6 Issue 329 Published - 14:00 UTC 08:00 EST 24-Nov-2004 Next Update - 14:00 UTC 08:00 EST 25-Nov-2004
little clear gif used for spacer
.
*

Birth rates for women aged 40-44 rose in 2003
Preliminary birth data for 2003 indicate that the birth rate for women aged 40-44 increased in 2003 while the rate for women aged 45-54 remain unchanged, according to a new report by the Centers for Disease Control and Prevention.  more

*
Low-glycemic load diet may improve ability to stay on diet longer
Low-glycemic load diets, those low in sugars with moderate levels of carbohydrates and not as low in fat and protein, may lower metabolism less when compared with low-fat diets, making the dieters feel less tired, cold and hungry, as well as improve cardiovascular risk factors, according to an article in the Nov. 24 issue of The Journal of the American Medical Association.  more

*
Researcher breaks down cholesterol mystery
You may not yet have heard of chylomicrons, but a nutritional scientist at the University of Alberta believes you will soon--especially if you care about preventing a stroke or heart attack.  more

 


*
Decline in cardiovascular disease reported in patients with diabetes
Adults with diabetes have experienced a 50 percent decline in the incidence rate for cardiovascular disease events in recent decades, according to a report in the 24 November issue of JAMA.  more

*
Inverse association found between selenium and colorectal cancer
A study in the 17 November Journal of the National Cancer Institute has found an inverse relationship between selenium blood levels and adenoma recurrence risk. Researchers from the Arizona Cancer Center, in collaboration with other cancer centers and government agencies such as NCI, CDC, and the U.S. Food and Drug Administration (FDA), as well as medical and public health schools across the country, found that higher blood selenium concentrations in study participants were associated with lower risk for developing recurrent adenomas.  more

*
First monoclonal antibody treatment for multiple sclerosis approved
FDA today licensed a new biologic approach to treat patients with relapsing forms of multiple sclerosis (MS) to reduce the frequency of symptom flare-ups or exacerbations of the disease. MS is a chronic, often disabling disease of the brain and spinal cord.  more

*
Prescribing information: Tysabri® (natalizumab)
Natalizumab is a monoclonal antibody bioengineered from part of a mouse antibody to closely resemble a human antibody. It is being marketed under the tradename Tysabri. The product is given intravenously once a month in a physician's office. Get product information in today's issue of Vidyya. more

 
little clear gif used for a space